Cipla: 2QFY02 results preview - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Cipla: 2QFY02 results preview

Oct 19, 2001

Cipla is expected to declare its second quarter results tomorrow. We expect the company to register a 23% rise in revenues, fuelled by an expected 84% growth in exports. On the back of increasing contribution of exports to the total revenues, we expect a 90 basis points rise in operating margins. Operating for first half are expected to remain flat as there was a drop of 100 basis point in 1QFY02, on the back of increase in marketing expenses.

(Rs m)2QFY012QFY02EChangeH1FY01H1FY02E% Change
Sales 2,697 3,316 23.0%5115629523.1%
Other Income 100 60 -40.0%176121-31.1%
Expenditure 2,063 2,507 21.5%3992491323.1%
Operating Profit (EBDIT) 634 809 27.7%1122138223.2%
Operating Profit Margin (%)23.5%24.4%21.9%22.0%
Interest 1 3 130.8%563.8%
Depreciation 45 48 6.7%839615.8%
Profit before Tax 687 818 19.0%1210140215.9%
Other Adjustments - - 0
Tax 170 140 -17.6%305280-8.2%
Profit after Tax/(Loss) 517 678 31.1%905112224.0%
Net profit margin (%)19.2%20.4%17.7%17.8%
No. of Shares (eoy) (m) 60.0 60.0 60.0 60.0
Diluted Earnings per share 34.5
P/E (at current price) 2430.9

Cipla Sales Mix
(Rs m)2QFY012QFY02E% Growth

The uncertainty prevailing over the export of generic Omeprazole, which is considered to be key earning opportunity for Cipla has further intensified. Just to recall, Cipla has an arrangement to supply Omeprazole (bulk drug) to Andrx. Andrx in turn claims to have a six month marketing exclusivity for the drug. However, the issue is caught in a long legal tangle. Recently, the US FDA had granted two more patents to AAI Pharma which has intensified the ongoing legal battle. Read more on the Omeprazole legal tangle.

In a recent development, the company has offered to supply Anthrax drug Ciprofloxacin to the US markets. Ciprofloxacin is currently under patent and hence only the patent holder viz, Bayer AG is allowed to sell the drug. Read more on Ciprofloxacin opportunity. However, the US administration announment to include other anti-biotics for anti-anthrax drive could open an opportunity for Cipla and other Indian companies. Cipla has the US FDA clearance for selling amoxyciline, (a substitute for ciprofloxacin) in the US markets.

At the current market price of Rs 1,155 the stock is trading at 26x FY02E earnings.

Equitymaster requests your view! Post a comment on "Cipla: 2QFY02 results preview". Click here!


More Views on News

Cipla's New Covid-19 Drug to Be Sold at Rs 59,750 Per Dose (Views On News)

May 25, 2021

The first batch of Roche's antibody cocktail has been launched in India, with the second batch to be made available by mid-June.

Cipla's Q4 Update: Net Profit Surges 68%; Company to Pay Rs 5 Dividend (Views On News)

May 17, 2021

Here's a rundown on the latest quarterly results of Cipla.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


Jun 18, 2021 (Close)